Free tool
FAERS Monitor: Viberzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206940 or its brand name (Viberzi, Eluxadoline). Reports on generic versions are filed under their own applications.
Reports
2,949
Serious
1,137
39% of reports
Hospitalization
567
Death reported
69
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use364
- abdominal pain352
- diarrhoea348
- constipation283
- pancreatitis278
- nausea220
- drug ineffective218
- abdominal pain upper210
- inappropriate schedule of drug administration162
- vomiting137
- fatigue118
- dizziness108
- wrong technique in product usage process108
- pain105
- incorrect dose administered90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2015 | 3 |
| 2016 | 837 |
| 2017 | 724 |
| 2018 | 266 |
| 2019 | 318 |
| 2020 | 184 |
| 2021 | 116 |
| 2022 | 95 |
| 2023 | 116 |
| 2024 | 92 |
| 2025 | 120 |
| 2026 | 77 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,210 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancreatitisSignal | 278 | 37.7 | 33.7 | 9,871 |
| inappropriate schedule of drug administrationSignal | 162 | 16.3 | 14.0 | 2,310 |
| abdominal painSignal | 352 | 10.8 | 9.8 | 3,153 |
| constipationSignal | 283 | 9.3 | 8.3 | 2,098 |
| abdominal pain upperSignal | 210 | 7.3 | 6.4 | 1,142 |
| diarrhoeaSignal | 348 | 3.8 | 3.5 | 753 |
| wrong technique in product usage processSignal | 108 | 3.8 | 3.2 | 222 |
| off label useSignal | 364 | 3.0 | 2.7 | 493 |
| incorrect dose administeredSignal | 90 | 2.8 | 2.3 | 104 |
| vomitingSignal | 137 | 2.1 | 1.8 | 77 |
| nausea | 220 | 2.0 | 1.7 | 110 |
| dizziness | 108 | 1.5 | 1.3 | 21 |
| pain | 105 | 1.2 | 1.0 | 4 |
| drug ineffective | 218 | 1.2 | 1.0 | 6 |
| fatigue | 118 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.